Treatment of lamivudine-resistant chronic hepatitis B infection

A multicenter retrospective study

Sun Jae Lee, Hyung Joon Yim, Seong Gyu Hwang, Yeon Seok Seo, Ji Hoon Kim, Eileen L. Yoon, Joong Min Lee, Bo Hyun Kim, Sang Jong Park, Young Min Park, Hong Soo Kim, Se Hwan Lee, Sang Hoon Ahn, Jeong Il Lee, Jin Woo Lee, In Hee Kim, Hyung Soo Kim, Sun Pyo Hong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives. To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods. The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results. A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9%) than in the ADV monotherapy (50/126, 39.7%) and ETV 1.0 mg monotherapy (19/48, 39.6%) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 ± 1.21 log10 IU/ml in the ADV plus LAM combination therapy group, 2.74 ± 1.74 log10 IU/ml in the ADV monotherapy group and 3.08 ± 1.97 log10 IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95% confidence interval, 1.000-1.006; p = 0.026). Conclusions. ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB.

Original languageEnglish
Pages (from-to)196-204
Number of pages9
JournalScandinavian Journal of Gastroenterology
Volume48
Issue number2
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Lamivudine
Chronic Hepatitis B
Multicenter Studies
Retrospective Studies
Infection
Hepatitis B virus
Therapeutics
DNA
Group Psychotherapy
Serum
adefovir dipivoxil
Korea
Viral Load
Multivariate Analysis
Odds Ratio
Confidence Intervals

Keywords

  • Adefovir
  • Antiviral resistance
  • Chronic hepatitis B
  • Combination drug therapy
  • Entecavir
  • Lamivudine
  • Multicenter study

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of lamivudine-resistant chronic hepatitis B infection : A multicenter retrospective study. / Lee, Sun Jae; Yim, Hyung Joon; Hwang, Seong Gyu; Seo, Yeon Seok; Kim, Ji Hoon; Yoon, Eileen L.; Lee, Joong Min; Kim, Bo Hyun; Park, Sang Jong; Park, Young Min; Kim, Hong Soo; Lee, Se Hwan; Ahn, Sang Hoon; Lee, Jeong Il; Lee, Jin Woo; Kim, In Hee; Kim, Hyung Soo; Hong, Sun Pyo.

In: Scandinavian Journal of Gastroenterology, Vol. 48, No. 2, 01.02.2013, p. 196-204.

Research output: Contribution to journalArticle

Lee, SJ, Yim, HJ, Hwang, SG, Seo, YS, Kim, JH, Yoon, EL, Lee, JM, Kim, BH, Park, SJ, Park, YM, Kim, HS, Lee, SH, Ahn, SH, Lee, JI, Lee, JW, Kim, IH, Kim, HS & Hong, SP 2013, 'Treatment of lamivudine-resistant chronic hepatitis B infection: A multicenter retrospective study', Scandinavian Journal of Gastroenterology, vol. 48, no. 2, pp. 196-204. https://doi.org/10.3109/00365521.2012.722671
Lee, Sun Jae ; Yim, Hyung Joon ; Hwang, Seong Gyu ; Seo, Yeon Seok ; Kim, Ji Hoon ; Yoon, Eileen L. ; Lee, Joong Min ; Kim, Bo Hyun ; Park, Sang Jong ; Park, Young Min ; Kim, Hong Soo ; Lee, Se Hwan ; Ahn, Sang Hoon ; Lee, Jeong Il ; Lee, Jin Woo ; Kim, In Hee ; Kim, Hyung Soo ; Hong, Sun Pyo. / Treatment of lamivudine-resistant chronic hepatitis B infection : A multicenter retrospective study. In: Scandinavian Journal of Gastroenterology. 2013 ; Vol. 48, No. 2. pp. 196-204.
@article{02670218096a4db6b05a0dd5840618ff,
title = "Treatment of lamivudine-resistant chronic hepatitis B infection: A multicenter retrospective study",
abstract = "Objectives. To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods. The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results. A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9{\%}) than in the ADV monotherapy (50/126, 39.7{\%}) and ETV 1.0 mg monotherapy (19/48, 39.6{\%}) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 ± 1.21 log10 IU/ml in the ADV plus LAM combination therapy group, 2.74 ± 1.74 log10 IU/ml in the ADV monotherapy group and 3.08 ± 1.97 log10 IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95{\%} confidence interval, 1.000-1.006; p = 0.026). Conclusions. ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB.",
keywords = "Adefovir, Antiviral resistance, Chronic hepatitis B, Combination drug therapy, Entecavir, Lamivudine, Multicenter study",
author = "Lee, {Sun Jae} and Yim, {Hyung Joon} and Hwang, {Seong Gyu} and Seo, {Yeon Seok} and Kim, {Ji Hoon} and Yoon, {Eileen L.} and Lee, {Joong Min} and Kim, {Bo Hyun} and Park, {Sang Jong} and Park, {Young Min} and Kim, {Hong Soo} and Lee, {Se Hwan} and Ahn, {Sang Hoon} and Lee, {Jeong Il} and Lee, {Jin Woo} and Kim, {In Hee} and Kim, {Hyung Soo} and Hong, {Sun Pyo}",
year = "2013",
month = "2",
day = "1",
doi = "10.3109/00365521.2012.722671",
language = "English",
volume = "48",
pages = "196--204",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Treatment of lamivudine-resistant chronic hepatitis B infection

T2 - A multicenter retrospective study

AU - Lee, Sun Jae

AU - Yim, Hyung Joon

AU - Hwang, Seong Gyu

AU - Seo, Yeon Seok

AU - Kim, Ji Hoon

AU - Yoon, Eileen L.

AU - Lee, Joong Min

AU - Kim, Bo Hyun

AU - Park, Sang Jong

AU - Park, Young Min

AU - Kim, Hong Soo

AU - Lee, Se Hwan

AU - Ahn, Sang Hoon

AU - Lee, Jeong Il

AU - Lee, Jin Woo

AU - Kim, In Hee

AU - Kim, Hyung Soo

AU - Hong, Sun Pyo

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Objectives. To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods. The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results. A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9%) than in the ADV monotherapy (50/126, 39.7%) and ETV 1.0 mg monotherapy (19/48, 39.6%) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 ± 1.21 log10 IU/ml in the ADV plus LAM combination therapy group, 2.74 ± 1.74 log10 IU/ml in the ADV monotherapy group and 3.08 ± 1.97 log10 IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95% confidence interval, 1.000-1.006; p = 0.026). Conclusions. ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB.

AB - Objectives. To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods. The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results. A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9%) than in the ADV monotherapy (50/126, 39.7%) and ETV 1.0 mg monotherapy (19/48, 39.6%) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 ± 1.21 log10 IU/ml in the ADV plus LAM combination therapy group, 2.74 ± 1.74 log10 IU/ml in the ADV monotherapy group and 3.08 ± 1.97 log10 IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95% confidence interval, 1.000-1.006; p = 0.026). Conclusions. ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB.

KW - Adefovir

KW - Antiviral resistance

KW - Chronic hepatitis B

KW - Combination drug therapy

KW - Entecavir

KW - Lamivudine

KW - Multicenter study

UR - http://www.scopus.com/inward/record.url?scp=84872701813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872701813&partnerID=8YFLogxK

U2 - 10.3109/00365521.2012.722671

DO - 10.3109/00365521.2012.722671

M3 - Article

VL - 48

SP - 196

EP - 204

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 2

ER -